Yirong Teng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yirong Teng has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Hongbo Yang
Fuwai Cardiovascular Hospital of Yunnan Province, Kunming, China
1 shared publication - Lei Feng
Yan’An Hospital Affiliated to Kunming Medical University, China
1 shared publication - Lirong Yang
Institute of Bioengineering, College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, China
1 shared publication - Qing Long
The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
1 shared publication Qinggang Hao
China Australia Chile United State Switzerland Netherlands Korea Japan
1 shared publication- Sheng Lu
Department of Orthopedics, The First People’s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by Wiley in Cardiology Research and Practice
- Vol. 2024 (1) , 1905996
Inhibiting H2AX Can Ameliorate Myocardial Ischemia/Reperfusion Injury by Regulating P53/JNK Signaling Pathway
Myocardial ischemia‐reperfusion (I/R) injury is a significant area of focus in cardiovascular disease research. I/R injury can increase intracellular oxidative stress, leading to DNA damage. H2AX plays a crucial role in DNA repair. This study utilized mouse and cell models of myocardial I/R to investigate the impact of H2AX on cardiomyocytes during I/R. This study initially assessed the expression of H2AX in MI/R mice compared to a sham surgery group. Subsequently, cardiac function, infarct area, and mitochondrial damage were evaluated after inhibiting H2AX in MI/R mice and a negative control group. Furthermore, the study delved into the molecular mechanisms by analyzing the expression of H2AX, P53, p‐JNK, SHP2, p‐SHP2, p‐RAS, parkin, Drp1, Cyt‐C, Caspase‐3, and Caspase‐8 in cardiomyocytes following the addition of JNK or P53 agonists. The results from western blotting in vivo indicated significantly higher H2AX expression in the MI/R group compared to the sham group. Inhibiting H2AX improved cardiac function, reduced myocardial infarct area, and mitigated mitochondrial damage in the MI/R group. In vitro experiments demonstrated that inhibiting H2AX could attenuate mitochondrial damage and apoptosis in myocardial cells by modulating the P53 and JNK signaling pathways. These findings suggested that inhibiting H2AX may alleviate myocardial I/R injury through the regulation of the P53/JNK pathway, highlighting H2AX as a potential target for the treatment of myocardial ischemia/reperfusion injury.
- 1 January 2024
- Published by Wiley in Cardiology Research and Practice
- Vol. 2024 (1) , 1905996
Open AccessInhibiting H2AX Can Ameliorate Myocardial Ischemia/Reperfusion Injury by Regulating P53/JNK Signaling Pathway
Myocardial ischemia‐reperfusion (I/R) injury is a significant area of focus in cardiovascular disease research. I/R injury can increase intracellular oxidative stress, leading to DNA damage. H2AX plays a crucial role in DNA repair. This study utilized mouse and cell models of myocardial I/R to investigate the impact of H2AX on cardiomyocytes during I/R. This study initially assessed the expression of H2AX in MI/R mice compared to a sham surgery group. Subsequently, cardiac function, infarct area, and mitochondrial damage were evaluated after inhibiting H2AX in MI/R mice and a negative control group. Furthermore, the study delved into the molecular mechanisms by analyzing the expression of H2AX, P53, p‐JNK, SHP2, p‐SHP2, p‐RAS, parkin, Drp1, Cyt‐C, Caspase‐3, and Caspase‐8 in cardiomyocytes following the addition of JNK or P53 agonists. The results from western blotting in vivo indicated significantly higher H2AX expression in the MI/R group compared to the sham group. Inhibiting H2AX improved cardiac function, reduced myocardial infarct area, and mitigated mitochondrial damage in the MI/R group. In vitro experiments demonstrated that inhibiting H2AX could attenuate mitochondrial damage and apoptosis in myocardial cells by modulating the P53 and JNK signaling pathways. These findings suggested that inhibiting H2AX may alleviate myocardial I/R injury through the regulation of the P53/JNK pathway, highlighting H2AX as a potential target for the treatment of myocardial ischemia/reperfusion injury.
- Open Access
- 30 May 2020
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Osteosarcopenia increasing the Risk of Falls, Fractures and Mortality?
INPLASY202050111 Osteosarcopenia increasing the Risk of Falls, Fractures and Mortality? Keywords: Osteosarcopenia; Falls; Fractures; Mortality. Download PDF – 202050111
- 30 May 2020
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Open AccessOsteosarcopenia increasing the Risk of Falls, Fractures and Mortality?
INPLASY202050111 Osteosarcopenia increasing the Risk of Falls, Fractures and Mortality? Keywords: Osteosarcopenia; Falls; Fractures; Mortality. Download PDF – 202050111